Insider Trading Update: Sheena Jonathan Sells Natera Stock to Cover Tax Obligations
Sheena Jonathan, the Director and Co-Founder of Natera, Inc. (NASDAQ:NTRA), recently sold 435 shares of common stock on February 3, 2026, at a price of $230.768, totaling approximately $100,384. The sale was made to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) and was part of a pre-arranged trading plan compliant with Rule 10b5-1(c). Following the transaction, Jonathan retains direct ownership of 263,161 shares of Natera common stock, along with indirect ownership of 21,782 shares each through the Caraluna 1 Trust and Caraluna 2 Trust, disclaiming beneficial ownership of the trust-held shares.
Natera has recently submitted a premarket approval application to the U.S. Food and Drug Administration for its Signatera CDx test, designed to detect molecular residual disease in muscle-invasive bladder cancer patients. This submission is supported by data from the phase 3 IMvigor011 clinical trial, demonstrating significant improvements in disease-free and overall survival for patients testing positive with Signatera. The company has also completed enrollment for its ACES-EMB trial, evaluating the potential of the Prospera Heart test to replace invasive biopsies in heart transplant monitoring, involving over 300 patients from 17 U.S. transplant centers.
Furthermore, Natera is set to present data from its EXPAND trial at the upcoming Society for Maternal-Fetal Medicine meeting in February 2026, focusing on validating the Fetal Focus screening test for assessing inherited disease-causing variants in fetuses. The company has introduced a new AI model to enhance cancer recurrence risk assessment by integrating various data types to improve the Signatera MRD test. Canaccord Genuity has maintained its Buy rating on Natera, highlighting strong preliminary fourth-quarter results with expected revenue growth of nearly 40% year-over-year, exceeding analyst expectations.
InvestingPro+ offers a data-driven approach to investment decisions, combining institutional-grade data with AI-powered insights to help investors make informed choices. While there are no guarantees in investing, leveraging data and insights can increase the likelihood of identifying successful investment opportunities. Stay informed and make smarter investment decisions with InvestingPro+.